Regents of the University of California’s Oric Pharmaceuticals ORIC Stock Holding History

Regents of the University of California’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-148,322	Closed	-$792K	–	43
2022 Q1	$792K	Hold	148,322	–	–	0.12%	33
2021 Q4	$2.18M	Buy	+148,322	New	+$2.31M	0.31%	19

Other funds holding ORIC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Regents of the University of California's ORIC Position: Q2 2022 in Review

Regents of the University of California sold out of Oric Pharmaceuticals (ORIC) in Q2 2022, closing a stake of 148,322 shares — an estimated $792K sold.

Regents of the University of California first reported a position in ORIC in Q4 2021 and held it in 2 quarters. The position peaked at $2.18M in Q4 2021. 83 funds tracked by Wall St. Rank hold ORIC as of Q2 2022.

Regents of the University of California reported no remaining Oric Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Regents of the University of California sold 148,322 Oric Pharmaceuticals shares in Q2 2022, an estimated $792K.
Regents of the University of California first reported a position in Oric Pharmaceuticals in Q4 2021 and held it in 2 quarters.
Regents of the University of California's Oric Pharmaceuticals position peaked at $2.18M in Q4 2021.
83 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2022.

Based on Regents of the University of California's 13F filing for Q2 2022, filed 5 Aug 2022.